U.S. Communications Stock News

Oriental Rise Holdings Limited ( NASDAQ:ORIS ) shareholders won't be pleased to see that the share price has had a very...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Those holding Frontier Group Holdings, Inc. ( NASDAQ:ULCC ) shares would be relieved that the share price has rebounded...

Over the past year, many Lennox International Inc. ( NYSE:LII ) insiders sold a significant stake in the company which...

We can readily understand why investors are attracted to unprofitable companies. For example, VirnetX Holding...

Energy Services of America Corporation ( NASDAQ:ESOA ) shares have had a horrible month, losing 26% after a relatively...

MYR Group's (NASDAQ:MYRG) stock is up by a considerable 18% over the past three months. Given that stock prices are...

Wondering if AtriCure at around $35 is quietly setting up a value opportunity, or if the market already has it priced just right? You are not alone in asking whether now is the moment to pay closer attention. The stock is up 16.2% year to date and 3.8% over the last month, even though it is still slightly down over 1 year and meaningfully lower over 3 and 5 years. This pattern hints at shifting sentiment and fresh expectations. Recent headlines have focused on AtriCure's progress in cardiac...

If you are wondering whether BWX Technologies is still worth considering after its huge run, or if the easy money has already been made, you are not alone in asking whether the current price really matches the company’s long term potential. Despite a powerful multi year climb with shares up 211.5% over 5 years and 198.8% over 3 years, the stock has recently cooled off, slipping 17.5% over the last month while still holding a 58.1% gain year to date and 37.4% over the past year. That pullback...

Topgolf Callaway Brands recently opened its 100th U.S. venue and 112th global location in New Braunfels, Texas, featuring 62 climate-controlled bays, a full-service bar and restaurant, and a range of tech-enabled games. The milestone venue, supported by a promotional campaign offering a chance at one year of free play, underscores Topgolf’s push to deepen customer engagement and expand its experiential footprint. Now we’ll examine how reaching the 100th U.S. venue milestone, alongside the...

If you are wondering whether MannKind at around $5.59 is a hidden opportunity or a value trap, you are not alone, and that is exactly what we are going to unpack. The stock has slipped around 15.3% year to date and 17.8% over the past year, but it is still up 18.9% over 3 years and 98.2% over 5 years, which highlights how sentiment and risk perception have shifted over time. Recent attention on MannKind has centered on its inhaled insulin Afrezza and its expanding footprint in pulmonary...

TC Bancshares (TCBC) has just posted its Q3 2025 numbers, with revenue at about $4.9 million, basic EPS of $0.08 and quarterly net income of roughly $0.33 million, setting the tone for a cautiously constructive update. The company has seen revenue move from around $4.1 million in Q3 2024 to about $4.9 million in Q3 2025, while basic EPS shifted from roughly $0.06 to $0.08 over the same period, giving investors a clearer read on how recent profitability trends are feeding into the latest...

Wondering if Open Text is quietly trading below what it is really worth? This article will walk through the numbers behind the story so you can decide if it deserves a spot on your radar. Despite being up 18.9% year to date and 10.2% over the past year, the stock has pulled back around 12.0% over the last month and is roughly flat over the last week at $33.59. This can signal a shift in sentiment or a new entry point for patient investors. Recent headlines have focused on Open Text's ongoing...

If you are wondering whether TG Therapeutics is still a smart bet at around $30 a share, you are not alone. This stock sits right in the crosshairs of growth hopes and valuation worries. Despite being down 8.3% over the last week, 9.1% over the past month, and 9.6% over the last year, the stock is still up 268.6% over three years, a pattern that often signals shifting risk perceptions rather than a simple boom-or-bust story. Recent headlines have focused on the company’s progress in...

If you have been wondering whether First Commonwealth Financial is quietly trading at a bargain or already priced for perfection, you are not alone. The stock closed at $16.50 recently, with returns of 7.9% over the last month but still down 8.8% over the past year, a pattern that hints at shifting views on its growth prospects and risk profile. Recent headlines around regional banks have focused on balance sheet resilience, deposit stability, and how smaller lenders are navigating a higher...

Wondering if Verisk Analytics is finally trading at a price that makes sense, or if the recent share moves are just noise in a data heavy story? The stock has inched up about 0.4% over the last week and 4.4% in the last month, but that comes after a tough stretch with shares still down 17.8% year to date and 22.4% over the past year, even though the three year and five year returns remain positive at 25.2% and 19.9% respectively. Recently, investors have been digesting updates around...

If you are wondering whether Consolidated Edison still looks sensible at today's price, or if the steady dividend giant is quietly getting expensive, you are in the right place to break down what the numbers really say. The stock has eased slightly in the short term, slipping about 2.0% over the last week and 0.6% over the last month, but it is still up 8.8% year to date and roughly 55.4% over five years. That pattern points to a sturdier long term story than recent noise suggests. Recent...

Wondering if ONE Gas is still good value after its latest run higher, or whether the easy money has already been made? This breakdown is designed to help you decide if the current price really makes sense. The stock is up 18.0% year to date and 11.6% over the past year, even after a recent 3.3% pullback in the last week and a modest 1.0% dip over the past month, which suggests investors are still broadly optimistic but increasingly selective on price. Recent attention around regulated...

If you are wondering whether Johnson Controls International is still worth buying after such a big run up, you are not alone. This is exactly what we are going to unpack today. The stock has been grinding higher, up about 0.5% over the last week, 0.8% over the past month, 46.0% year to date, and 42.1% over the last year. These gains build on multi-year returns of 85.8% over three years and 182.9% over five years. Recently, investors have been reacting to a steady drumbeat of news around...

United Natural Foods (UNFI) opened fiscal Q1 2026 with revenue of about $7.8 billion and a basic EPS loss of roughly $0.07, alongside a trailing 12 month EPS of around negative $1.67 and net income of negative $101 million, keeping the bottom line in the red despite steady sales. The company has seen quarterly revenue move from $7.9 billion in Q1 2025 to $7.8 billion in Q1 2026, while basic EPS losses narrowed from about $0.35 a year ago and sat against a trailing 12 month revenue base of...

If you are wondering whether Stoke Therapeutics is still worth buying after its huge run, you are not alone. This article is going to unpack what the current price is really implying about the company. The stock has pulled back about 4.5% over the last week, but is still up roughly 14.2% over the past month and an eye catching 164.5% year to date, with a 132.7% gain over the last year and 321.6% over three years, despite being down 40.7% over five years. Those swings are not happening in a...

Kura Oncology recently reported that it completed the first U.S. commercial sale of KOMZIFTI (ziftomenib), its newly FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia, which also triggered a US$135,000,000 milestone payment from partner Kyowa Kirin expected before year-end 2025. This first sale, combined with KOMZIFTI’s inclusion in NCCN guidelines as a Category 2A recommended option, signals early clinical acceptance and provides an...

If you have been wondering whether Cadence Design Systems at around $317 a share is still worth buying, you are not alone. This article is going to walk through what the current price really implies. The stock is up 3.8% over the last week, down 5.2% over the past month, modestly ahead 6.8% year to date, but down 2.0% over the last year after a 98.0% 3 year and 175.3% 5 year run. Those mixed returns come as investors digest a steadier phase for semiconductor and AI related spending, with...